Ecto-NOX disulfide-thiol exchanger 1 promoter (eNOX1pr)

The Ecto-NOX disulfide-thiol exchanger 1 promoter (eNOX1pr) is a specialized DNA regulatory sequence utilized in gene therapy to enable disease-specific expression of therapeutic genes. It is a central component of the HGT-Cardio-1 vector, an adeno-associated virus (AAV) therapy developed by Houston Gene Therapeutics to treat cardiovascular conditions such as atherosclerosis and vascular inflammation (Houston Gene Therapeutics [1.2.1]). The promoter contains specific inflammation-responsive elements (IREs) that are activated by pathological triggers, including oxidized low-density lipoprotein (Ox-LDL), Angiotensin II, and lipopolysaccharide (LPS). These elements bind transcription factors like NF-κB and NRF1, which are upregulated during inflammatory stress, ensuring that therapeutic proteins (e.g., IL-10 or FoxP3) are produced only at the site of disease (Gene, 2013 [1.3.1]). This 'built-in safeguard' minimizes systemic exposure and potential side effects by restricting gene expression to inflamed tissues. The eNOX1pr is derived from the regulatory region of the ENOX1 gene, which naturally functions in plasma membrane electron transport and redox homeostasis (GeneCards [1.1.5]). Its small size (under 0.6 kb) facilitates its use in viral vectors with limited packaging capacity.

Other names

eNOX1 promoterInflammation-responsive elements driving eNOX1pr promoterPathology-responsive promoterHGT-Cardio-1 promoterENOX1 promoter

The eNOX1pr promoter contains specific inflammation-responsive elements (IREs) that bind transcription factors such as NF-κB, NRF1, and STAT3, which are activated by pro-inflammatory signaling pathways. This allows the promoter to drive the expression of downstream therapeutic genes specifically in response to pathological stimuli like Ox-LDL or Angiotensin II.